![share_log](https://usnewsfile.moomoo.com/20230625000012291e57d0213b0.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
牛牛AI助理已提取核心訊息
Heart Test Laboratories, a medical technology company, has reported minimal revenues of $19,000 for the fiscal year ended April 30, 2024, a 280% increase from the previous year's $5,000. The cost of sales rose 100% to $6,000, resulting in a gross margin of $13,000, up 550% from $2,000 in the prior year. Operating expenses totaled $6.3 million, with research and development costs at $2.9 million, marking a 17% increase due to consulting for Cloud Platform development and FDA submission support. Selling, general, and administrative expenses decreased by 6% to $3.4 million, attributed to lower insurance premiums and reduced IPO-related professional fees. The company's net loss widened by 4% to $6.6 million. Heart Test Laboratories has not yet received FDA clearance for its products and relies on equity and debt financing for operations. The company...Show More
Heart Test Laboratories, a medical technology company, has reported minimal revenues of $19,000 for the fiscal year ended April 30, 2024, a 280% increase from the previous year's $5,000. The cost of sales rose 100% to $6,000, resulting in a gross margin of $13,000, up 550% from $2,000 in the prior year. Operating expenses totaled $6.3 million, with research and development costs at $2.9 million, marking a 17% increase due to consulting for Cloud Platform development and FDA submission support. Selling, general, and administrative expenses decreased by 6% to $3.4 million, attributed to lower insurance premiums and reduced IPO-related professional fees. The company's net loss widened by 4% to $6.6 million. Heart Test Laboratories has not yet received FDA clearance for its products and relies on equity and debt financing for operations. The company's cash position improved to $5.8 million, up from $1.7 million the previous year, following capital raises through Common Stock and Warrant sales. The company's future plans include FDA submissions for its MyoVista wavECG device and MyoVista Insights Cloud Platform, aiming for the first quarter of 2025 and mid-2025, respectively. Heart Test Laboratories' success hinges on FDA clearances and additional funding for sales launches and R&D.
醫療科技公司Heart Test Laboratories報告稱,截至2024年4月30日的財政年度,其收入爲19,000美元,比前一年的5,000美元增長了280%。銷售成本增加了100%,達到6,000美元,導致毛利率上升到13,000美元,較上一財年的2,000美元增長了550%。運營費用總計637萬美元,其中研發費用爲290萬美元,由於爲Cloud Platform開發和FDA提交支持提供諮詢服務而增加了17%。銷售、一般和行政費用下降了6%,歸因於保險費用更低以及IPO相關專業費用減少。公司的淨虧損擴大了4%,達到660萬美元。Heart Test Laboratories尚未獲得F...展開全部
醫療科技公司Heart Test Laboratories報告稱,截至2024年4月30日的財政年度,其收入爲19,000美元,比前一年的5,000美元增長了280%。銷售成本增加了100%,達到6,000美元,導致毛利率上升到13,000美元,較上一財年的2,000美元增長了550%。運營費用總計637萬美元,其中研發費用爲290萬美元,由於爲Cloud Platform開發和FDA提交支持提供諮詢服務而增加了17%。銷售、一般和行政費用下降了6%,歸因於保險費用更低以及IPO相關專業費用減少。公司的淨虧損擴大了4%,達到660萬美元。Heart Test Laboratories尚未獲得FDA批准其產品,依靠股權和債務融資進行運營。該公司的現金頭寸提高了至580萬美元,高於上一財年的170萬美元,通過普通股和認股權證銷售籌集資金。該公司未來計劃包括爲其MyoVista wavECG設備和MyoVista Insights Cloud Platform提交FDA申請,分別瞄準2025年第一季度和2025年中期。Heart Test Laboratories的成功取決於FDA的批准和額外的銷售推介和研發資金。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了